Thursday, March 20, 2025 12:43:21 PM
We're currently at about 1.4M Market Cap with $600K Revs YTD, thru Sept 2024.
By their own admission, we are many months from any announced Licensing deals.
What if they do get a Licensing deal? What will it be for? $2M Cash. With Milestones. Big deal.
Sohm owes a lot of money to Aguilar...so any upfront Licensing payments will go straight to payout for him, and other debt-holders are also waiting in line too.
So, imo, it's going to be a long while before "Licensing" affects the Sohm bottom line.
The only thing that will change that is if they get a large Licensing deal. I'm not confident they've got the goods or expertise anymore.
Imo, who wants to pay .0007, for a Company that has maybe $700-800K in sales, plenty of debt, and Fails to deliver.
I suppose there's people that like to tie up money for indefinite periods of time.
Regarding "Substantial and verifiable"...the only thing I would have Trust in is if they Announced a Licensing deal, that also included the name of the Partner, would need to be a known Pharma, and if the Partner was directly quoted in the PR.
...AND the PR would need to have the $$$ size of the Licensing Contract, including the upfront Payment, and payment horizons.
Would Sohm do that...I have my doubts.
By their own admission, we are many months from any announced Licensing deals.
What if they do get a Licensing deal? What will it be for? $2M Cash. With Milestones. Big deal.
Sohm owes a lot of money to Aguilar...so any upfront Licensing payments will go straight to payout for him, and other debt-holders are also waiting in line too.
So, imo, it's going to be a long while before "Licensing" affects the Sohm bottom line.
The only thing that will change that is if they get a large Licensing deal. I'm not confident they've got the goods or expertise anymore.
Imo, who wants to pay .0007, for a Company that has maybe $700-800K in sales, plenty of debt, and Fails to deliver.
I suppose there's people that like to tie up money for indefinite periods of time.
Regarding "Substantial and verifiable"...the only thing I would have Trust in is if they Announced a Licensing deal, that also included the name of the Partner, would need to be a known Pharma, and if the Partner was directly quoted in the PR.
...AND the PR would need to have the $$$ size of the Licensing Contract, including the upfront Payment, and payment horizons.
Would Sohm do that...I have my doubts.
Recent SHMN News
- SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery • ACCESS Newswire • 11/06/2025 02:30:00 PM
- SOHM Notes FDA's Evolving Gene-Editing Framework in Context of Ongoing ABBIE Platform Development • ACCESS Newswire • 11/04/2025 02:30:00 PM
